These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 29966356

  • 21. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
    Ayala-Breton C, Barber GN, Russell SJ, Peng KW.
    Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
    [Abstract] [Full Text] [Related]

  • 22. Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.
    Gambini E, Reisoli E, Appolloni I, Gatta V, Campadelli-Fiume G, Menotti L, Malatesta P.
    Mol Ther; 2012 May; 20(5):994-1001. PubMed ID: 22354378
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The molecular basis of herpesviruses as oncolytic agents.
    Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C.
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
    [Abstract] [Full Text] [Related]

  • 27. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
    Conner J, Braidwood L, Brown SM.
    Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
    [Abstract] [Full Text] [Related]

  • 28. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED, Meza-Perez S, Bevis KS, Randall TD, Gillespie GY, Langford C, Alvarez RD.
    J Ovarian Res; 2016 Oct 27; 9(1):70. PubMed ID: 27784340
    [Abstract] [Full Text] [Related]

  • 29. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, Yamaue H.
    Int J Cancer; 2013 Jan 15; 132(2):485-94. PubMed ID: 22729516
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y.
    Gene Ther; 2006 Apr 15; 13(8):705-14. PubMed ID: 16421599
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
    Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E.
    Cancer Res; 2006 Dec 15; 66(24):11840-50. PubMed ID: 17178881
    [Abstract] [Full Text] [Related]

  • 36. Oncolytic HSV as a vector in cancer immunotherapy.
    Li H, Zhang X.
    Methods Mol Biol; 2010 Dec 15; 651():279-90. PubMed ID: 20686972
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL.
    PLoS Pathog; 2013 Jan 15; 9(1):e1003155. PubMed ID: 23382683
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH/gL in the absence of gD and cellular receptors.
    Atanasiu D, Cairns TM, Whitbeck JC, Saw WT, Rao S, Eisenberg RJ, Cohen GH.
    mBio; 2013 Feb 26; 4(2):. PubMed ID: 23443004
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.